Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.
Moll
S
S
University of North Carolina School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chapel Hill, NC 27599, USA. smoll@med.unc.edu
Lindley
C
C
Pescatore
S
S
Morrison
D
D
Tsuruta
K
K
Mohri
M
M
Serada
M
M
Sata
M
M
Shimizu
H
H
Yamada
K
K
White
G C
GC
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010599:Pharmacokinetics; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012995:Solubility; D018180:Thrombomodulin / Q000008:administration & dosage*; D013925:Thromboplastin / Q000037:antagonists & inhibitors
C472045:ART123; D000925:Anticoagulants; D011994:Recombinant Proteins; D018180:Thrombomodulin; D013925:Thromboplastin